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Summary: We have previously reported a correlation between depression in 
patients with idiopathic Parkinson’s disease and decreased concentrations of 
the cerebrospinal fluid content of the serotonin metabolite, 5-HIAA. To further 
examine this relationship, we repeated the study in a new cohort of patients 
while they remained on dopaminergic medications, conducted follow-up inter- 
views and examinations in our original cohort, and conducted an open trial of 
the serotonin precursor, 5-hydroxytryptophan in a group of new patients with 
depression. We were again able to demonstrate a significant reduction in ce- 
rebrospinal 5-HIAA in depressed patients in comparison to controls and pa- 
tients without depression. Demented patients with Parkinson’s disease, par- 
ticularly those with concurrent depression, had the lowest values of 5-HIAA. 
No new cases of depression occurred in our original cohort after 2% years of 
follow-up, and depression remitted following conventional or experimental 
treatment in four patients. Depression improved in six of the seven new pa- 
tients following oral 5-hydroxytryptophan. Three of these patients allowed a 
repeat lumbar puncture, and the concentration of 5-HIAA increased following 
5-hydroxytryptophan. These three studies support our hypothesis that depres- 
sion in idiopathic Parkinson’s disease is associated with a reduction in brain 
serotonin. However, it also suggests that other factors, biological or environ- 
mental, may be causal factors. Key Words: Parkinson’s disease- 
Serotonin-5-Hydroxytryptophan. 
INTRODUCTION 
Depression is the most common mental disturbance in patients with Parkinson’s 
disease (PD). Gotham et al. (1) reviewed 14 recent studies including over 1500 
patients and estimated the mean prevalence to be 46%, ranging from 20% to as 
high as 90% in various studies. In two earlier investigations (2,3), we found one of 
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two types of depressive disorders in nearly half of the patients we investigated: 
major depression and dysthymic disorder. We have also found that 25% of de- 
pressed patients become depressed prior to the onset of the motor manifestations 
of PD (4). 
The cause of depression in PD is unknown. Against a reactive depression is the 
lack of an association between depression and duration of illness, degree of dis- 
ability, seventy of parkinsonism, or response to medications (5).  Others disagree, 
and consider depression to be related to the degree of disability and the severity 
of illness in PD because its prevalence is similar to that in patients with chronic 
illnesses, such as arthritis (1). We have observed a relationship between depres- 
sion and reduced cerebrospinal fluid (CSF) levels of the metabolite of serotonin, 
5-hydroxyindoleacetic acid (5-HIAA), during a dopamine agonist withdrawal pe- 
riod (2,3). While this does not imply that depression is endogenous, it suggests 
that depression in patients with PD may be related to alterations in biogenic 
amines. A relationship between depression and serotonin has also been found in 
some depressed patients without PD (6,7). This relationship between depression 
and reduced CSF 5-HIAA in PD suggests that reduced serotonin in brain may 
be related to the cause of depression. 
To clarify the relationship between depression in PD and serotonin, we con- 
ducted three studies based upon our previous work: 
(a) We measured the CSF content of 5-HIAA in patients with PD while they 
remained on dopamine agonists and related this information to clinical evidence of 
depression. This was a change from our previous methods in that we eliminated 
the drug withdrawal period prior to lumbar puncture in order to determine if the 
relationship would still exist under these more “natural” conditions. 
(b) We conducted an open trial of oral L-5-hydroxytryptophan (L-SHTP), the 
precursor to serotonin, in depressed patients with PD to examine its effect on 
mood. 
(c) We also conducted follow-up interviews and examinations in previously 




Forty-one consecutively encountered patients, from an outpatient urban hos- 
pital setting, considered to have idiopathic PD, agreed to participate in the study 
protocol. No subject was selected because of the presence of a change in behavior 
or because of a particular type of behavioral disorder. However, it was difficult to 
avoid selection bias because patients had to volunteer to be hospitalized. After 
giving informed consent, all subjects entered a General Clinical Research Center 
(GCRC) for the psychiatric, neuropsychological, neurological, and CSF- 
biochemical studies to be described. Subjects remained on regular doses of 
dopamine agonists throughout the study; no patient was taking psychotropics or 
anticholinergics. 
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Psychiatric Diagnoses 
A structured psychiatric interview for diagnoses, according to the Diagnostic 
and Statistical Manual of Mental Disorders, third edition (DSM-111) (8). was con- 
ducted in every patient within 24 h of the lumbar puncture. We were particularly 
interested in the diagnosis of any depressive disorder or dementia, and used the 
Structured Clinical Interview for DSM-111 (SCID) (9) to determine the presence or 
absence of relevant symptoms to establish whether diagnostic criteria were met. 
Neuropsychological Studies 
Each patient received a battery of neuropsychological tests measuring memory, 
language, attention, constructional ability, and general cognition. The diagnosis of 
dementia required all the criteria described in the DSM-III(8) for primary degen- 
erative dementia; neuropsychological studies were used to confirm the diagnosis 
of dementia when it was suspected. 
CSF Studies 
A lumbar puncture for CSF studies was performed after 18 h bedrest. Twenty 
milliliters of CSF were removed for the biochemical studies, which were con- 
ducted using high pressure liquid chromatography with amperometric detection 
by a method we described earlier (10). 
L-~-HTP Trial 
Seven parkinsonian patients with major depression and low CSF 5-HIAA, de- 
fined as below 19.5 ng/ml of CSF from earlier investigations (2,3), began an open 
trial of oral LJ-HTP. The initial daily dose was 75 mg; this was increased by 25 
mg/day at intervals of about 3 days. Doses were increased until patients reported 
some reduction in depressive symptoms or to a maximal dose of 500 mg/day. The 
final dosage was maintained for 4 months. In some patients carbidopa was added 
to prevent diarrhea and other unpleasant effects of 5-HTP. However, carbidopa 
was often taken in conjunction with levodopa and there was no need for more. 
The Hamilton Depression Rating Scale (HDRS) (1 l) ,  Columbia University PD 
rating scale (12), and Schwab and England activities of daily living rating (ADL) 
(13) were performed prior to beginning the treatment and at monthly intervals 
during the open trial. Repeat lumbar punctures were performed in three of the 
seven patients who received oral 5-HTP; CSF 5-HIAA levels were repeated to 
assess any change that may have resulted from 5-HTP. 
Longitudinal Studies 
Forty-nine of 56 patients from our previous studies (2,3) were reevaluated for 
depression and dementia. The mean duration between assessments was 2.5 years. 
A semi-structured interview was used to determine the presence or absence of 
depression or dementia. This examination included the HDRS score and the mod- 
ified Mini-Mental State Examination (mMMS) (4). A family member or another 
informant was also interviewed if necessary. We were unable to examine 17 
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patients personally, but sufficient information could be gathered by telephone 
from the patient's personal physician and family members regarding current clin- 
ical status to reach a diagnostic conclusion. Psychiatric diagnoses were derived 
from the interviews and we used the DSM-111 criteria (8) as guides for the diag- 
nosis of dementia and depression. 
RESULTS 
Replication Study 
Of the 41 new subjects, there were 27 men and 14 women. Their mean age was 
66.3 years (range 48-83 years), mean years of education was 14.2 (range 5-19 
years), and mean duration of illness was 7.6 years (range 2-30 years). Seven met 
criteria for major depression, 15 met criteria for primary degenerative dementia, 
and three met criteria for both. The remaining 16 patients were free of dementia 
or depression. A comparison of the CSF biogenic amine metabolites in these four 
groups is summarized in Table 1. There was a significant reduction in CSF 5- 
HIAA in patients with major depression compared to those without depression or 
dementia (F = 3.22, p < 0.05). Demented patients also had a reduction in CSF 
S H I M ,  and their values did not differ significantly from the depressed or the 
nondepressed groups. Patients who were both demented and depressed had the 
greatest reduction in this metabolite but these values did not differ significantly 
from the depressed group. All patient groups differed from the comparison group 
composed of individuals that were neither depressed or demented. CSF- homo- 
vanillic acid (HVA) vaned in the groups, but all patients were taking dopamine 
agonists precluding interpretation. The presence of depression or  dementia did 
not relate to dosage of levodopa or CSF-HVA level. Corrected MHPG values did 
not differ between groups. 
L-SHTP Trial 
Table 2 summarizes the results of this study. Improvement in depressive symp- 
toms was noted in six of the seven patients who continued in the study as indi- 
cated by the reduction in the HDRS (11). One patient (patient no. 5 )  did not 
improve and eventually required electroconvulsive therapy. No significant change 
TABLE 1. Biogenic amine metabolite values in four patient groups expressed in 
CSF nglml 
Not depressed or Major Depressed and 
demented Demented depression demented 
N 16 15 7 3 
Age 59.8a (7.7) 75.2b (6.2) 64.0a (4.4) 61.3a (12.2)* 
HVA 54.4 (31.7) 52.1 (31.4) 92.6 (60.1) 52.1 (31.6) 
MHPG + 3.9 (1.9) 3.7 (2.3) 3.9 (2.9) 3.6 (4.9) 
5-HIAA 19.la (5.9) 15.5ab (5.7) 12.lb (6.7) 10.9b (5.4)* 
~ ~ ~~~ ~~ ~ ~ ~~ ~ 
Values in parentheses are standard deviations, p values are for ANOVA's comparing all group 
means for each variable. Means with the same letters do not differ significantly in post-hoc analyses. 
* Differences were significant p c 0.05. +CSF-MHPG corrected as described previously (10). 
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PDE %ADL HDRS 
49 80% 22 
39 80% 14 
38 65% 21 
67 60% 12 
11 95% 18 
23 50% 18 
11.5 95% 17 
4 months 5-HTP 
PDE %ADL HDRS 
41 80% 11 
31 80% 3 
37 70% 13 
43 85% 6 
13 90% 22 
34.5 60% 7 
5.5 95% 13 
PDE, Parkinson’s disease evaluation scale (13); %ADL, percentage of independence in activities of 
in signs or symptoms of PD (12) was noted in any of the seven patients, and ADL 
scores (13) remained the same during the open 4 month trial. 
CSF 5-HIAA increased in all three subjects who had repeat lumbar punctures 
(Table 3). In two of these subjects, CSF studies were repeated more than once; 
mood improved and 5-HIAA levels increased with higher dosages of 5-HTP. 
Parkinsonian signs and symptoms did not change significantly in these patients. 
Longitudinal Study 
Of the original 49 patients from earlier studies (3,4), 13 died. Postmortem 
examination was performed in five of these patients which confirmed the clinical 
diagnosis of PD in all five. Three of the five had coincident pathological features 
of Alzheimer’s disease (AD) (14). None of the others allowed postmortem exam- 
ination. Only one of the 49 patients could not be located. Among the 21 patients 
with either major depression or dysthymic disorder, four remitted (three with 
major depression and one with dysthymic disorder). In two patients, this remis- 
sion was the result of standard treatment, and in another remission followed 
5-HTP treatment. All three of the patients with major depression had CSF 5- 
HIAA levels below 19.5 ng/ml. The patient with dysthymic disorder improved 
without treatment. 
No new cases of depression were encountered in any of the 28 other patients 
during the follow-up. This group included nine patients with low CSF levels of 
5-HIAA and no evidence of depression at the time of the original studies (2,3). 
daily living (12), and HDRS, Hamilton Depression Rating Scale (11). 
DISCUSSION 
The replication component of this investigation, combined with our earlier stud- 
ies (2,3), strengthens the “serotonin hypothesis” for major depression in PD, and 
TABLE 3.  CSF 5-HIAA afrer 5-HTP administration 
Baseline After 5-HTP 
Patient Age Sex 5-HIAA HVA 5-HIAA HVA 
1 69 F 9 mg/d  95 mg/d  33 m g l d  71 mglml 
44 rng/ml 24 mg/ml 82 mg/ml 2 48 M 10 mg/ml 
3 55 F 25 mg/ml 62 m g / d  39 rnglrnl 122 mdml 
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suggests that the relationship can be detected when patients remain on dopamine 
agonists. However, two observations raise suspicion about its specificity. First, if 
lower concentrations of brain serotonin predispose to depression, we would have 
anticipated depression to develop in one of the nine nondepressed patients with 
low CSF 5-HIAA levels. The absence of new depression in the longitudinal study 
may simply reflect the small sample size. A larger cohort would be required to 
determine the incidence rate of depression in PD in general and would need to 
include patients with low CSF 5-HIAA as well. The absence of depression in the 
follow-up patients may simply indicate that the biochemical deficit is not the only 
prerequisite for depression, or that serotonin levels may not play a critical role in 
the chronicity of depressive disorders in PD. 
Second, our finding of reduced CSF 5-HIAA levels in demented patients, par- 
ticularly those with depression, was not anticipated. Postmortem investigations of 
PD and AD have indicated that the brain serotonin content may be reduced (15), 
and CSF 5-HIAA is reduced in patients with advanced AD (16). The cause of this 
reduction in AD and its clinical correlate are not established. Three of the de- 
mented patients (one with depression and dementia) from the follow-up cohort 
had pathological features of AD and PD, and were reported earlier (14). More- 
over, presynaptic markers for serotonin were reduced in all three patients (14). 
Subsequently, a patient with dementia and depression from the new study also 
had pathological features of AD on cortical biopsy, and reduced levels of CSF 
Van Pragg and de Haan (7) consider reduced serotonin levels to increase the 
risk of depression because of the putative effect of serotonin on mood regulation. 
Serotonin levels are lower in the brains of elderly depressives who die of natural 
causes and suicide victims than in age-matched controls (6,7). Stanley and asso- 
ciates (17) have found that imipramine binding, a presynaptic serotonin marker, is 
reduced in the frontal cortex of suicides, and Ninan et al. (18) reported that CSF 
5-HIAA is lower in schizophrenics who attempt suicide than in those who do not 
(18). Thus, while depletion of brain serotonin may not directly cause depression, 
the relationship may implicate an important biochemical link to mood disorders 
in PD. 
Dopamine does not appear to have a major role in depression; depression does 
not correlate with CSF-HVA. The elevated CSF-HVA levels in the current study 
probably reflect the administration of oral levodopa. Quantitative measures of 
disease severity or functional disability, and failure of levodopa to consistently 
alleviate depressive symptoms, also indicate the lack of an association between 
dopamine and depression. Traditional antidepressants improve depression, but 
have little effect on the motor manifestations of PD (5 ) .  
The open trial of 5-HTP in depressed patients with PD was encouraging and also 
supports a role for serotonin in depression. Prior to this study the dose range for 
treatment of depression in PD was not established, and the time-frame over which 
to expect drug effects was not clear. We did not treat severely depressed or 
suicidal patients because we were uncertain that 5-HTP would be effective. These 
patients have the lowest concentrations of CSF 5-HIAA and brain serotonin (6,7). 
Previous studies of 5-HTP in PD were intended for motor manifestations; Chase 
5-HIAA. 
Movement Disorders. Vol. 3, No.  3 ,  1988 
SEROTONIN A N D  DEPRESSION IN PD 243 
et al. (19) found 5-HTP, in higher doses than we used, worsened PD but Sano and 
Taniguchi (20) found improvement. In nonparkinsonian depressed patients, only 
those with low CSF 5-HIAA concentrations respond favorably to 5-HTP treat- 
ment (21). Whether LJ-HTP is better than conventional antidepressants in PD 
remains to be determined. Our purpose was to examine the hypothesis which 
related depression to serotonin concentrations. The repeat CSF studies indicated 
an increase in CSF 5-HIAA levels when depression improved. A controlled in- 
vestigation of this compound or a serotonergic antidepressant would seem an 
appropriate next step. 
Follow-up of our previously examined patients showed that depression is rel- 
atively persistent, although it did resolve in four of the 21 patients. No new cases 
of depression were observed. While the incidence of depression in PD has not 
been investigated, the incidence of nonbipolar depression in people without PD 
has rarely been investigated. Boyd and Weissman (22) reviewed several studies 
and concluded that the lifetime risk for depression in the general population was 
8-12% for men and 20-26% for women. The incidence of depression is 
-0.0&0.2% for men and 0 . 2 4 6 %  for women. The incidence increases with 
negative life events, and is higher in medically ill patients and the elderly (22,23). 
We would have expected depression to be more frequent in the follow-up of our 
patients, but the small number of patients with low CSF 5-HIAA may have pre- 
cluded a reasonable study of incidence. 
Sampling and assessment techniques account for much of the variation in stud- 
ies of the prevalence of depression in PD. Diagnosis based on depression scales is 
not always accurate because these scales assess the presence of symptoms of 
depression, not the presence of criteria for diagnosis. Self-reporting scales are 
also difficult to interpret because many of the items confound manifestations of 
depression and PD. However, when a criterion based interview is used, the 
HDRS score (1 1) usually reflects the severity of depression. Although the prev- 
alence of depression in PD is greater than that expected for healthy persons (3, 
the prevalence in comparison to other equally disabling illnesses is still the subject 
of controversy (1). 
In the current study, we have added further evidence for our hypothesis that 
depression in patients with PD is related to a reduction in brain serotonin. The 
relationship may be present in demented patients with PD who are also depressed. 
While interesting, this observation needs to be confirmed by others. Our study 
does not distinguish between a reactive or primary depression in PD. Neverthe- 
less, there is clearly a biochemical correlate that may allow for the development 
of a rational treatment for this behavioral problem. 
ADDENDUM 
After the submission of our paper we encountered the work of Kostic et al. 
(Kostic VS, Djuricic BM, Covickovic-Sternic N, Bumbasirevic L, Nikolic M, 
Mrsulja BB. Depression and Parkinson’s disease: possible role of serotonergic 
mechanisms. J Neurol 1987;234:94-6). They essentially replicated our study in a 
cohort of 26 patients with Parkinson’s disease. The levels of CSF-5-HIAA were 
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significantly lower in the depressed parkinsonian group than in the nondepressed 
group or in the control population. There was no relationship between the severity 
of motor manifestations of Parkinson’s disease and depression. This is the first 
study, to our knowledge, replicating our previous investigation. 
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